期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
眼底激光治疗糖尿病视网膜病变的临床效果分析
1
作者 王熙 《中文科技期刊数据库(引文版)医药卫生》 2023年第4期102-105,共4页
分析在眼底激光治疗能否提高糖尿病视网膜病变患者的治疗效果。方法 从2021年5月-2022年5月期间门诊糖尿病视网膜病患者中随机抽取例30例,采用平均分组的方式将这些视网膜患有疾病的患者纳入实验和对照两个组别,对照组:常规治疗,实验组... 分析在眼底激光治疗能否提高糖尿病视网膜病变患者的治疗效果。方法 从2021年5月-2022年5月期间门诊糖尿病视网膜病患者中随机抽取例30例,采用平均分组的方式将这些视网膜患有疾病的患者纳入实验和对照两个组别,对照组:常规治疗,实验组:激光联合治疗,从有效率、临床症状是否得到有效的缓解、以及生活质量等方面进行评估,以此来确定眼底激光治疗对患者的重要作用。结果 通过两组患者的临床表现发现,实验组治疗效果显著(P<0.05)。实验组在视物模糊、视力减退、视野缩小、眼底出血等方面消除时间均有所降低,消除时间短于对照组(P<0.05)。在患者生活质量比较上,实验组患者的生活质量远远高于对照组(P<0.05)。结论:在对患有糖尿病视网膜病变这种疾病的治疗方法的研究中,采用常规治疗方法并不能取得很好的效果,在常规治疗基础上结合眼底激光治疗,治疗效果提升较为明显,值得临床的推广。 展开更多
关键词 激光治疗 糖尿病患者 视网膜病患者变 临床效果 分析
下载PDF
Erythropoietin Receptor Positive Circulating Progenitor Cells and Endothelial Progenitor Cells in Patients with Different Stages of Diabetic Retinopathy 被引量:5
2
作者 Liu-mei Hu Xia Lei +9 位作者 Bo Ma Yu Zhang Yan Yan Ya-lan Wu Ge-zhi Xu Wen Ye Ling Wang Guo-xu Xu Guo-tong Xu Wei-ye Li 《Chinese Medical Sciences Journal》 CAS CSCD 2011年第2期69-76,共8页
Objective To investigate the possible involvement of erythropoietin (EPO)/erythropoietin receptor (EPOR) system in neovascularization and vascular regeneration in diabetic retinopathy (DR). Methods EPOR positive... Objective To investigate the possible involvement of erythropoietin (EPO)/erythropoietin receptor (EPOR) system in neovascularization and vascular regeneration in diabetic retinopathy (DR). Methods EPOR positive circulating progenitor cells (CPCs: CD34^+) and endothelial progenitor cells (EPCs: CD34^+KDR^+) were assessed by flow cytometry in type 2 diabetic patients with different stages of DR. The cohort consisted of age- and sex-matched control patients without diabetes (n=7), non-prolif- erative DR (NPDR, n=7), proliferative DR (PDR, n=8), and PDR complicated with diabetic nephropathy (PDR-DN, n=7). Results The numbers of EPOR^+ CPCs and EPOR^+ EPCs were reduced remarkably in NPDR corn pared with the control group (both P(0.01), whereas rebounded in PDR and PDR-DN groups in varying degrees. Similar changes were observed in respect of the proportion of EPOR^+ CPCs in CPCs (NPDR vs. control, P(0.01) and that of EPOR^+ EPCs in EPCs (NPDR vs. control, P〈0.05). Conclusion Exogenous EPO, mediated via the EPO/EPOR system of EPCs, may alleviate the impaired vascular regeneration in NPDR, whereas it might aggravate retinal neovascularization in PDR due to a rebound of EPOR^+ EPCs associated with ischemia. 展开更多
关键词 circulating progenitor cells endothelial progenitor cells erythropoietin re-ceptor diabetic retinopathy
下载PDF
Progress in the study of cancer-associated retinopathy in breast cancer patients
3
作者 Guangyan Ji Lei Xing +4 位作者 Jianbo Huang Lingquan Kong Ziwei Wang Guosheng Ren Kainan Wu 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第10期566-571,共6页
Cancer-associated retinopathy (CAR) typically has a sudden or progressive onset of severe visual loss and an ominous association with an occult malignancy which contains breast cancer. Pathologically, CAR is the degen... Cancer-associated retinopathy (CAR) typically has a sudden or progressive onset of severe visual loss and an ominous association with an occult malignancy which contains breast cancer. Pathologically, CAR is the degeneration of photoreceptors. But the precise mechanism has not been fully established, CAR may result from autoimmune mediated apoptosis. And in recent years, there also have been some results demonstrating that tumor derived angiogenic factors such as VEGF may also confer the development of CAR, which may offer novel avenues for the therapeutic intervention in CAR. Early initiation of immunosuppressive therapy is critical for vision preservation. Future developments in rapid identification and longitudinal quantification of antibody levels would enable individualized management in these patients. The goal of this review was to analyze the epidemiology, the clinical features, the diagnosis and management of retinopathy in the context of recent advances in the elucidation of breast cancer-associated retinopathy (BCAR) pathogenesis. 展开更多
关键词 paraneoplastic retinopathy autoimmune retinopathy cancer-associated retinopathy (CAR) RECOVERIN cytotoxicT-lymphocyte immune therapy
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部